Hospital admissions · patients with schizophrenia
1 finding from 1 review
Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Global state: average score: long term (+ 26 weeks) Global Assessment Scale (GAS). Scale from: 0 to 100. · patients with schizophrenia
2 findings from 1 review
Mental state · patients with schizophrenia
2 findings from 1 review
Adverse effects: tardive dyskinesia: long term (+ 26 weeks) as defined in each study · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes adverse effects: tardive dyskinesia: long term (+ 26 weeks) as… compared with MAINTENANCE THERAPY (very low certainty).
2 findings from 1 review
Cost‐effectiveness · patients with schizophrenia
2 findings from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
2 findings from 1 review
Relapse · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes relapse: medium term (13‐25 weeks) as defined in each study compared with PLACEBO (very low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
1 finding from 1 review
Global state Global Assessment Scale (GAS) · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: tardive dyskinesia: medium term (13‐25 weeks) as defined in each study · patients with schizophrenia
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) may leads to higher relapse: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (low certainty).
1 finding from 1 review
Hospital admissions · patients with schizophrenia
INTERMITTENT (EARLY‐BASED) probably leads to higher hospitalisation: long term (+ 26 weeks) as defined in each study compared with MAINTENANCE THERAPY (moderate certainty).
1 finding from 1 review